Effects of TNF on Phospholipase A Activity in Cancer Patients
Author Information
Author(s): Waldemar Pruzanski, Matthew L. Sherman, Donald W. Kufe, Peter Vadas
Primary Institution: University of Toronto; Dana-Farber Cancer Institute, Harvard Medical School
Hypothesis
Does intravenous infusion of recombinant human TNF increase circulating phospholipase A activity in patients with malignancies?
Conclusion
Infusion of recombinant human TNF significantly increases circulating phospholipase A activity in cancer patients.
Supporting Evidence
- 21 of 23 patients showed marked increases in serum PLA2 activity after rh-TNF infusion.
- PLA2 activity peaked at 18 hours after the start of the infusion.
- A significant correlation was found between the dose of rh-TNF and the maximum increase in PLA2 activity.
Takeaway
When cancer patients received a special treatment called TNF, their bodies made a lot more of a substance called phospholipase A, which is important for inflammation.
Methodology
Twenty-three cancer patients received intravenous infusion of rh-TNF, with varying doses over 24 hours or 5 days, and serum PLA2 activity was measured.
Limitations
The study does not explore the long-term effects of TNF infusion on PLA2 activity or its clinical implications.
Participant Demographics
Patients included 9 men and 14 women, aged 25 to 73 years, with various types of cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website